top of page
News
Search
iQure Pharma Receives Approval for iQ-007 Phase 1 First in Human Study
Princeton, NJ, March 12, 2025 ─  iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...
Mar 12
iQure Pharma’s iQ-007 Receives FDA Orphan Drug Designation for Dravet’s Syndrome
Princeton, NJ, January 23, 2025 ─  iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...
Jan 23
iQure Pharma Secures $4M Funding – Advancing Phase 1 Clinical Trial for iQ-007
Princeton, NJ, January 07, 2025 ─  iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...
Jan 7
iQ-007 Zebrafish Screening Reveals Positive Results in Other Neurodegenerative Diseases
Princeton, NJ, June 21 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech  company dedicated to the development of new epilepsy...
Jun 20, 2024
JPM Week
No Abuse
bottom of page